Oral HMAs May Provide Safer and More Effective Treatment Options for MDS
OncLive,
Guillermo Garcia-Manero, MD The FDA-approved oral formulation of decitabine/cedazuridine (Inqovi), as well as the…
S172: PHASE 1/2 STUDY OF ORAL DECITABINE/CEDAZURIDINE IN COMBINATION WITH VENETOCLAX IN TREATMENT‐NAÏVE HIGHER‐RISK MYELODYSPLASTIC SYNDROMES OR CHRONIC MYELOMONOCYTIC LEUKEMIA
Overview of attention for article published in HemaSphere, August 2023
Altmetric Badge
About this Attention Score
-
In the top 25% of all research outputs scored by Altmetric
-
Good Attention Score compared to outputs of the same age (76th percentile)
-
Good Attention Score compared to outputs of the same age and source (68th percentile)
Readers on
- mendeley
- 2 Mendeley